Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias.

导出 OA

翻译打印收藏纠错

作者： Min Chul,Kwon ^[1] ; Jan Willem,Thuring ^[2] ; Olivier,Querolle ^[2] ; Xuedong,Dai ^[3] ; Tinne,Verhulst ^[1] ; Vineet,Pande ^[2] ; Ann,Marien ^[1] ; Dries,Goffin ^[1] ; Daniela V,Wenge ^[4] ; Hong,Yue ^[5] ; Jevon A,Cutler ^[4] ; Cyrus,Jin ^[5] ; Florian,Perner ^[4] ; Shanna M,Hogeling ^[6] ; Paul L,Shaffer ^[7] ; Frank,Jacobs ^[2] ; Petra,Vinken ^[2] ; Wei,Cai ^[3] ; Vikki,Keersmaekers ^[1] ; Filmon,Eyassu ^[1] ; Balpreet,Bhogal ^[7] ; Karin,Verstraeten ^[1] ; Sara,El Ashkar ^[1] ; Jennifer A,Perry ^[4] ; Prathiba,Jayaguru ^[8] ; Laura,Barreyro ^[8] ; Anna,Kuchnio ^[1] ; Nicolas,Darville ^[2] ; Daniel,Krosky ^[7] ; Gregor,Urbanietz ^[2] ; Bie,Verbist ^[9] ; James P,Edwards ^[7] ; Glenn S,Cowley ^[7] ; Robert,Kirkpatrick ^[7] ; Ruth,Steele ^[7] ; Lucille,Ferrante ^[10] ; Christina,Guttke ^[8] ; Nikki,Daskalakis ^[10] ; E Christine,Pietsch ^[11] ; David M,Wilson ^[2] ; Ricardo,Attar ^[8] ; Yusri,Elsayed ^[11] ; Eric S,Fischer ^[5] ; Jan Jacob,Schuringa ^[6] ; Scott A,Armstrong ^[4] ; Kathryn,Packman ^[12] ; Ulrike,Philippar ^[1]

作者单位： Discovery Oncology, Janssen R&D, Beerse, Belgium. ^[1] Discovery Product Development and Supply, Janssen R&D, Beerse, Belgium. ^[2] Discovery Product Development and Supply, Janssen R&D, Shanghai, China. ^[3] Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.;Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA. ^[4] Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.;Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA. ^[5] Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. ^[6] Discovery Product Development and Supply, Janssen R&D, Spring House, PA. ^[7] Translational Research, Janssen R&D, Spring House, PA. ^[8] TMEDS, Janssen R&D, Beerse, Belgium. ^[9] Early Development, Janssen R&D, Spring House, PA. ^[10] Discovery Oncology, Janssen R&D, Spring House, PA. ^[11] Early Development, Janssen R&D, Cambridge, MA. ^[12]